In this review, the most relevant and current epidemiological data, the main clinical, laboratory and therapeutical aspects of leprosy are presented. Detailed discussion of the main drugs used for leprosy treatment, their most relevant adverse effects, evolution of the therapeutic regimen, from dapsone as a monotherapy to the proposed polychemotherapy by World Health Organization (WHO) can be found in this CME. We specifically highlight the drug acceptability, reduction in treatment duration and the most recent proposal of a single therapeutic regimen, with a fixed six months duration, for all clinical presentations, regardless of their classification.
INTRODUCTION
Leprosy is an infectious and contagious chronic disease, caused by Mycobacterium leprae, an obligate intracellular bacillus, that affects mainly the skin, nerves and mucous membranes. 1, 2 It can also affect the eye, nose, joints, lymph nodes, internal organs and bone marrow, especially in multibacillary patients (MB). 1, 2 In the majority of cases, it is transmitted from person to person through contact with patients that have a high bacillary index and haven't been treated. 1, 2 In 2008, a new species of mycobacterium was identified in Mexican MB patients -Mycobacterium lepromatosis. 3 Recently, M. lepromatosis was also found in paucibacillary patients. 4 The disease has a 2-to 5-year course for paucibacillary patients and a 5-to 10-year course for multibacillary patients. 5 Humans are the main natural reservoir of the bacillus. There are reports of armadillos and squirrels naturally infected by M. leprae, with the hypothesis formulation that some cases could have been a conse-
EPIDEMIOLOGY OF LEPROSY
The introduction of the multidrug therapy (MDT) or polychemotherapy, recommended by WHO in 1981, led to significant changes in leprosy epidemiology. 13 Obviously, the reduction in treatment duration, impacted on the prevalence; from over 5 million cases in the 1980s, there was a reduction to less than 200,000 cases in 2015. [13] [14] [15] Graph 1 shows the global prevalence rates of leprosy detection for the period between 2002 and 2015. The excessive optimism with the global reduction of disease prevalence, led WHO, without robust evidence, to establish the global goal of leprosy elimination as a public health issue in 1991, meaning less than one person affected per 10,000 inhabitants. 16 With this prevalence rate, it was believed that leprosy transmission would be reduced and the disease would naturally disappear.
Prevalence is decreasing in many countries, however the detection rates remain the same in some areas. In 2015, all over the world, 210,758 new cases of leprosy were detected, corresponding to the detection coefficient of 3.2 cases per 100,000 inhabitants and prevalence of 0.29/10,000 inhabitants. The global current data indicates that leprosy elimination goal was achieved.
14 Of all new cases, thereafter. As, after finshing the scheduled tretament, the patient is removed from the data. 13, [17] [18] [19] There has been marked reduction on leprosy prevalence after MDT introduction and decreased in treatment length; however, this therapeutic regimen have had no impact on transmission. 20 It is still necessary to improve early detection of cases, prevention measures for disabilities, trainning of health professionals, stimulate research for better understanding of disease transmission, newdrugs and new therapeutical regimens, in order to cease the transmission cycle. 21 Leprosy elimination took a wrong path, and the goals were proposed without solid scientific evidence that would grant them appropriate support. [22] [23] [24] 26 The best denomination would be interpolar, for these patients do not simply present with the two polar forms of the disease. Clinically, they can present with features close to the T or L poles, and also intermediate forms.
In the 1960s, Ridley and Jopling proposed modifying Madrid's classification, based on the histological and immunological aspects subdividing borderline (B) patients into borderline-tuberculoid (BT), borderline-borderline (BB) and borderline-lepromatous (BL). This classification is essential in research. In the majority of cases, the initial clinical manifestation of these patients is also indeterminate leprosy.
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In general, patients with I, T and BT leprosy have negative Lepromatous leprosy (LL) in its initial phase, is characterized by erythematous-hypopigmented slightly edematous macules.
CLINICAL MANIFESTATIONS
The edges can progressively became indistinct in relation to the normal skin, increase in size and coalesce, forming extensive edematous areas, that can be disseminated or generalized. Papules and nodules (hansenomas or lepromas) can appear on the edematous areas ( Figures 3 and 4) . Madarosis, xerosis, edema of the extremities and cyanosis of the palmar and plantar regions can be found. These manifestations are generally bilateral and symmetrical. Thickening of peripheral nerves with bilateral loss of sensibility, in "boot" or "glove", and ocular abnormalities are also common. 2, 27 Cutaneous ulcers, plantar trophic ulcers with bone loss, severe eye manifestations and systemic manifestations can occur in LL patients without appropriate treatment.
Borderline leprosy (BL) group is statistically the largest one in number of diagnosed patients, when clinical and laboratory criteria are correctly applied. In our setting, the term "dimorphic" has also been used to refer to these cases. As previously seen, this term is incorrect, because usually, two forms of leprosy are not seen at the same time. In practice, we keep the English word bordeline, classifying the patients as borderline-tuberculoid (BT), borderline-borderline (BB) and borderline-lepromatous (BL). In all BL patients, the involvement of peripheral nerve trunks are common. 
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syndrome, peripheral neuropathy and nephrotic syndrome can be included.
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The first reports of dapsone resistance are from the 1960s -experimentally proven by Pettit Dermatology Division -DNDS) established that established that MB patients would be would be treated with the combination of dapsone and rifampicin in the first three months, followed by dapsone alone. 47 In the majority of health care falcilities, dapsone was almost always prescribed indefinitely. Upon suspicios of dapsone resistance, it was replaced by clofazimine. 47 At that time, the combination of DDS and rifampicin was rejected, since patients with potential dapsone resistance would be undergoing rifampicin as monotherapy and could develop resistance to the latter. 
MAIN DRUGS USED FOR LEPROSY TREATMENT
The treatment of leprosy is an outpatient treatment, using 1982 WHO standardized regimens, which is basically three first-line drugs: dapsone, rifampicin and clofazimine. 13 This association is known as MDT or polychemotherapy (PCT).
Sulfone (diaminodiphenyl sulfone -DDS), also known as dapsone, has mainly a bacteriostatic action, with low bactericidal activity. 33 It probably acts as an antagonist of the para-aminobenzoic acid (PABA), preventing its utilization in the synthesis of folic acid by M. leprae. It is well-tolerated, with many side effects that, in the majority of cases, do not lead to discontinuation of treatment.
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The first therapeutic trial with dapsone was performed by 
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, in 1972, also showed similar results to dapsone. In almost all studies, CLF was used as monotherapy. The pigmentation caused by this drug probably limited its large-scale use. This is one of the explanations for the rare cases of M. leprae resistance to this drug.
Afterwards, CLF started to be used in large scales, becoming a major component of the multidrug therapy. 13 Admittedly, this drug, associated to RMP and DDS, would be key for the prevention of drug resistance. This theory was proven along over 30 years of MDT.
The most important side effects of CLF are skin pigmentation, xerosis, hypersensitivity to light, gastrointestinal manifestations and edema of the lower limbs. The pigmentation can be attenuated upon reducing sun exposure. In many cases, after discontinuing the medication, the pigmentation persists for one or more years. [36] [37] [38] [39] [40] [41] In general, the edematous areas of bacillary patients become intensely pigmented because of drug build up. Minocycline is the only tetracycline with bacterial action on M. leprae; it is superior to clarithromycin, but substantially inferior to RMP. It is used in the dose of 100 mg/day. Its main side effects are skin, mucous membranes and teeth pigmentation; gastrointestinal and central nervous system abnormalities can also occur. 61 This drug has been used as an alternative in a small number of cases.
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Clarithromycin has bactericidal action on M. leprae; it is used in the dose of 500 mg/day. In experimental studies, this macrolide destroyed 99% of the bacilli in 28 days; and in 55 days, 99.9% of the bacilli become unviable. 64 The main side effects are gastrointestinal disturbances, mainly nausea, vomiting and diarrhea. 
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For the paucibacillary adults, its recommended: dapsone -100 mg/day, and rifampicin -600 mg, once a month in supervised doses for six months. For the multibacillary, clofazimine -100 mg/ day'+ 300mg/month was added to the PB regimen, with 24 months duration or until the bacilloscopy is negative. 13 For adults that weigh less than 35 kg, the doses are adjusted, rifampicin being 450 mg/ month and the dapsone 50 mg (1 to 2 mg/ kg/weight/day). The dose of clofazimine is variable, 50 to 100 mg/day. For children, the same regimens, in the following doses: up to five years of age, dapsone 25 mg/day, rifampicin 150 to 300 mg/ month, clofazimine 100 mg/ month and 100 mg/week; from 6 to 14 years of age, dapsone 50 to 100 mg/day, rifampicin, 300 to 450 mg/month and clofazimine, 150mg/week and 150 to 200 mg/month. 13, 80, 81 In the first few years when MDT was implemented, the majority of multibacillary patients was treated until bacilloscopy were not viable, and were progressively eliminated in alogarithmic rate of 0.66/year of its initial bacillary load, this theory was confirmed a few years after this decision was made. 29, 60 During this period, some articles demonstrated that the combination of a single dose of rifampicin -600mg, minocycline100mg and ofloxacin -400mg, provided cure for a high percentage of patients with a single cutaneous lesion. This regimen, known as ROM, showed efficacy of over 80% in a study of series of cases; it was not implemented in the majority of the endemic countries.
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In 1998, WHO recommended the reduction of MDT for multibacillary patients for 12 months . 30 For PB the treatment remained the same six months regimen. In some studies, it was observed that the efficacy of 12 doses was similar to the 24-month regimen. 85, 86 Therefore, since the initial 1981 recommendation for MDT, the treatment has been modified regarding its length: initially, it was done until bacilloscopy became negative; afterwards, 24 doses; and, currently, 12 months. The efficacy has been similar, regardless of the duration of therapy. Analysis of reactions frequency among MB patients wasn't markedly different between the groups that received regular twelve or six months treatment (Graph 2). 96 There was no statistically significant difference when the four groups were compared, U and R-MDT, with BI lower and higher than three (Graph 3). The analysis of BI reduction was also performed through the estimation of MI mean reduction as a function of time and not as the mean reduction of BI for all patients as in the traditional regression analyses, that tend to over estimate results. This analysis showed a higher reduction in BI of patients treated with the regular regimen; however, this reduction was not significantly higher than the one from patients treated with U-MDT (Graphs 4 and 5).
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UNIFORM (U-MDT) FOR PB AND MB PATIENTS, WITH NO NEED FOR CLINICAL OR LABORATORY CLASSIFICATION FOR TREATMENT PURPOSES
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A descriptive epidemiological study based on U-MDT/CT-BR to verify PB patient satisfaction regarding the use of clofazimine, identified that 6.9% (15/217) manifested the desire to discontinue the medication due to changes in skin color. These results showed that the introduction of clofazimine in the treatment of PB patients did not negatively impact patient satisfaction. 98 The final results of the study were recently submitted for publication.
The introduction of MDT in 1981 was responsible for important developments in leprosy control programs. 13 However, the three drugs combination as a therapeutical regimen is not ideal: it has only one bactericidal agent,treatment lenght is long, cutaneous pigmentation can be marked and there can be other adverse effects.
These reasons point towards the need for new studies, with new therapeutical regimens. 99 However, the disease complexity, meth- 
Choose the correct option:
a) The diagnosis of new patients with disabilities does not indicate late diagnosis; b) Programs that have high rates of MB patients among the new cases probably need to reassess control strategies, particularly those related to early diagnosis; c) Programs with high rates of PB patients among the new cases do not necessarily need to reassess control strategies, particularly those related to early diagnosis; d) All options are incorrect.
20.
In order to achieve reduction in leprosy transmission, we need: a) Good structure for the control programs and adequate training of health care professionals, including in universities; b) Short duration treatment regimens; c) In the future, the vaccination and probably prophylactic treatment;
d) All options are correct.
